A phase II clinical trial of an immune regulator, NP001, identified slower progression of ALS in patients with higher C-reactive protein levels at baseline but failed to reach significance in the whole cohort [ 125 ].
← all excerpts
The Molecular Link Between TDP-43, Endogenous Retroviruses and Inflammatory Neurodegeneration in Amyotrophic Lateral Sclerosis: a Potential Target for Triumeq, an Antiretroviral Therapy.
1
—
—